Genmab A/S announced that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination across disease settings in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) at the 30thEuropean Hematology Association (EHA) Congress, being held in Milan, Italy, and virtually, June 12-15, 2025. Two oral presentations will feature data from the Phase 1/2 EPCORE®? NHL-2 trial evaluating epcoritamab plus rituximab and ifosfamide-carboplatin-etoposide (R-ICE) in patients with relapsed/refractory (R/R) DLBCL eligible for autologous stem cell transplantation, and the Phase 1/2 EPCORE NHL-5 trial evaluating epcoritam ab plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) in previously-untreated patients with DLBCL.
Additionally, results from the Phase 1/2EPCORE NHL-1 and NHL-3 trials, including three years of follow-up in patients with R/R DLBCL and FL treated with epcoritamab monotherapy, will be presented as a poster. All abstracts accepted for presentation have been published and may be accessed online via the EHA Open Access Library. Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody®?
technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab are designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.
Epcoritamab (approved under the brand name EPKINLY®? in the U.S. and Japan, and TEPKINLY®? in The EU) has received regulatory approval in certain lymphoma indications in several territories.
Epcoritamab has received regulatory approval in certain leukemia indications in several territories. EpCoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. & Japan, with AbbVie responsible for further global commercialization.
Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and Abb Vie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamib as a monotherapy in patients with R/RDLBCL compared to investigators choice chemotherapy (NCT04628494), a trial evaluating epcoritAMab in combination with rituximab and lenalidomide (R2) compared to chemoimmunotherapy in patients with R/R/R FL (NCT05409066), a trial evaluating epcor it in combination with rituxIMab and lenalidomide in patients with R/R FL (N CT05409066), a study evaluating epcoritamab in combination with ritiumimab and lenalidomab and lenalidomide(R2) compared to chemOimmunotherapy in patients with DLBCL.
